Analyst Ratings January 27, 2026

BTIG trims Synchrony Financial price target to $96, cites expense and loan-growth headwinds

Firm keeps Buy rating as 2026 seen as transition year; expense control and new partnerships central to upside

By Priya Menon SYF
BTIG trims Synchrony Financial price target to $96, cites expense and loan-growth headwinds
SYF

BTIG has lowered its price target on Synchrony Financial (SYF) to $96 from $100 while retaining a Buy rating, following the lender's 2026 guidance. The analyst adjustment reflects higher expense assumptions and reduced loan-growth expectations, even as BTIG describes the stock's post-guidance sell-off as "overly draconian." Synchrony met fourth-quarter 2025 EPS expectations but missed revenue forecasts, and the firm must manage costs to reach long-term efficiency targets as new partnership-driven growth is expected to materialize by mid-2026.

Key Points

  • BTIG lowered its price target on Synchrony Financial from $100 to $96 while keeping a Buy rating; this follows the company’s 2026 guidance described as "inline to slightly worse."
  • The revised target incorporates higher expense assumptions and lower loan-growth expectations; BTIG values SYF at 10x and 9x 2026 and 2027 EPS estimates, and notes shares trade at 7.8x the midpoint 2026 EPS guidance of $9.30.
  • Execution of new partnerships with Walmart, a Lowe’s commercial card offering, and Amazon BNPL services - expected to show results by Q2 2026 - and restoration of efficiency ratios to 32%-33% are key to the recovery thesis.

BTIG reduced its price objective on Synchrony Financial to $96.00 from $100.00 but maintained a Buy recommendation on the stock. The change follows the company's 2026 guidance, which BTIG analyst Vincent Caintic characterized as "inline to slightly worse" than the firm had anticipated. BTIG said the guidance prompted roughly a 6% decline in the share price that the firm judged "overly draconian."

The analyst note incorporates revised assumptions for higher expenses and slower loan growth. BTIG continues to value Synchrony at 10x and 9x its 2026 and 2027 EPS estimates, respectively, while pointing out that the shares currently trade at just 7.8x the midpoint of the 2026 EPS guidance, which the company set at $9.30.

Market data referenced by InvestingPro shows that analyst price targets for SYF span a range from $72 to $103, with the stock trading at $72.99 at the time of the report. InvestingPro also lists a current P/E ratio for SYF of 8.06 and a PEG ratio of 0.43, which reflects a relatively low price-to-earnings multiple compared with the firm's expected growth. The platform rates Synchrony with an overall financial health score of 3.12 and labels that rating as "GREAT," signaling solid fundamentals despite recent volatility.

BTIG described 2026 as a "transition year toward growth" for Synchrony. The research note ties a recovery in growth and the firm's valuation to successful execution of a series of partnership initiatives. Specifically, BTIG highlighted potential upside from new and expanded partnerships with Walmart, a commercial card relationship with Lowe's, and buy-now-pay-later services on Amazon. The firm expects clearer evidence of these initiatives translating into growth by the second quarter of 2026.

At the same time, BTIG underscored the importance of managing expenses. The research firm noted that Synchrony needs to bring its efficiency ratio back toward the long-term guidance range of 32% to 33% from a projected 35% for 2026. BTIG framed top-line growth driven by investment spending as the route to improved long-term efficiency, but cautioned that expense control is a prerequisite for reaching the company's stated targets.

In its most recent reported period, Synchrony posted fourth-quarter 2025 results with earnings per share of $2.04, which matched analysts' expectations. Revenue for the quarter came in at $3.79 billion, below the forecasted $3.84 billion and missing estimates by 1.3%. BTIG and other market participants focused on that revenue shortfall as an important signal about near-term performance relative to expectations.

BTIG's updated target and the analyst commentary reflect a view that Synchrony's medium-term upside depends on converting partnership growth initiatives into measurable loan and fee growth while simultaneously reining in expenses to regain historical efficiency levels. The firm's valuation framework retains a multiple-based approach versus 2026 and 2027 EPS, but the near-term path is conditioned on execution against the initiatives and expense trajectory outlined above.


Context for market participants

  • Investors should weigh the reduced price target against the maintained Buy rating and the company's current trading multiples.
  • Key operational levers are partnership rollouts and expense discipline, which will influence loan growth and efficiency metrics.
  • Recent quarterly results showed EPS in line with estimates but a modest revenue miss that bears watching.

Risks

  • Expense trajectory - Synchrony projects a 35% efficiency ratio for 2026, above its long-term guidance of 32%-33%, meaning failure to control costs could hinder return-to-target efficiency and pressure margins. This impacts the banking and consumer finance sectors.
  • Execution risk on partnership-driven growth - BTIG's valuation depends on new partnership wins translating into measurable loan and fee growth by mid-2026; delays or weaker-than-expected results would affect the payments and retail-finance segments.
  • Top-line pressure - the company reported fourth-quarter 2025 revenue of $3.79 billion, missing the $3.84 billion forecast by 1.3%, which highlights near-term revenue risks for investors in financial and consumer-credit markets.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026